Clinical trials of HDL cholesterol-raising therapy: What have we learned about the HDL hypothesis from AIM-HIGH?

Current Atherosclerosis Reports

Volumn 14, Issue 3, 2012, Pages 190-192

  Rosenson, Robert S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiovascular events; Clinical trials; HDL functionality; HDL particle concentration; High density lipoprotein; Niacin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CEREBRAL REVASCULARIZATION; CLINICAL TRIAL (TOPIC); DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; EARLY TERMINATION OF CLINICAL TRIAL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; METABOLIC SYNDROME X; NOTE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

EID: 84861229902     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0236-1     Document Type: Note

References (14)

1. The AIM-HIGH Investigators, BodenWE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patient with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67.
2. The AIM-HIGH Investigators. The role of niacin in raising highdensity lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J. 2011;161:538-43.
3. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-10. (Pubitemid 47481452)
4. Rosenson RS, Brewer Jr HB, Chapman MJ, Fazio S, Hussain MM, Kontush A, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011;57:392-410.
5. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and rish of vascular disease. JAMA. 2010;302:1993-2000.
6. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care. 2008;32:1087-91.
7. Airan-Javia SL, Wolf RL, Wolfe ML, Tadesse M, Mohler E, Reilly MP. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. Am Heart J. 2009;157:687.e1-8.
8. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (in press).
9. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-35.
10. Tan HC, Tai ES, Sviridov D, Nestel PJ, Ng C, Chan E, et al. Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus. J Clin Lipidol. 2011;5:467-73.
11. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, et al. Cholesterol efflux potential and anti-inflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc. 2011;30:1430-8.
12. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/anti-inflammatory properties of highdensity lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751-6. (Pubitemid 37498976)
13. Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 2010;30:968-75.
14. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121:110-22.